The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.

Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for ...

Hims & Hers Health, Inc., the leading health and wellness platform, today announced an acquisition that will further verticalize the company’s long-term ability to deliver personalized medications.

Hims & Hers announced it has acquired a U.S.-based peptide facility based in California. The company said the acquisition will enable the ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...

Recently approved treatments for generalized myasthenia gravis (gMG), including complement and neonatal Fc receptor (FcRn) ...

Hims & Hers Health, Inc. (NYSE:HIMS) shares stumbled Friday afternoon. The company, the leading health and wellness platform, today announced an acquisition that will further verticalize the company’s ...

The OCEANIC-AF trial has raised concerns about factor XI inhibitors. Should physicians still bet on this class of ...

Research reveals promising advancements of Ce6-GFFY in colorectal cancer treatment. Colorectal cancer (CRC) is a highly ...

For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporte ...

NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended ...

Researchers have discovered that stomach cancer cells connect with nearby sensory nerves, forming electrical circuitsthat ...